Brii hires Gilead's China general manager Luo to drive expansion

Rogers Yongqing Luo (Brii Biosciences)

Brii Biosciences has hired Rogers Yongqing Luo away from Gilead to serve as general manager of its Chinese operation. The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession. 

When Luo joined Gilead in 2016, the big biotech was yet to win approval to sell key products such as hepatitis C blockbuster Sovaldi in China. Luo leaves Gilead in a different state than he found it. Under Luo’s leadership, Gilead won approval for eight drugs in China between 2017 and 2020 and got four products—Vemlidy, Epclusa, Harvoni and Genvoya—on the National Reimbursement Drug List. 

In July, Gilead CEO Daniel O'Day told investors the company was experiencing significant volume growth in China, despite COVID-19. Gilead backed up the growth with spending, citing its expansion in China as a driver of a $325 million increase in selling, general and administrative expenses in 2019.

Webinar

Digitize remote site monitoring with Box

Box will discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing.

At Brii, Luo has a chance to replicate what he achieved at Gilead. Brii is a smaller biotech but, having launched with $260 million in 2018, has built a broad pipeline that could deliver multiple approvals in the coming years. Brii’s most advanced assets are hepatitis B candidates BRII-835 and BRII-179, phase 2 programs for which the biotech has the Chinese rights. 

Brii is looking to Luo to help guide those and other products to market and make successes of them commercially. That will require Luo and his new colleagues to navigate a changing landscape. 

“The environment is changing rapidly in China, with a need for companies to anticipate and respond with deep insight, disruptive access technologies, novel purchasing and healthcare delivery strategies—at the national, regional and local level,” Luo said in a statement.

Luo gained the experience needed to navigate that environment as Gilead’s general manager for China and, before that, as VP of Roche China and general manager of Novartis, North China.

Brii disclosed the appointment of Luo alongside news that it has hired Ankang Li, Ph.D., as chief financial officer. Li, who like Luo will work out of Shanghai, comes to Brii from Terns Pharmaceuticals, where he also served as CFO. The appointment gives Brii a CFO with experience leading biotech IPOs from his time as executive director of healthcare investment banking at Goldman Sachs.

Suggested Articles

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.

In 2018, Astellas spent $405 million to buy out long-term biotech partner Potenza and its small group of early-stage cancer drugs.